Literature DB >> 17308130

Contraception today.

Giuseppe Benagiano1, Carlo Bastianelli, Manuela Farris.   

Abstract

Modern contraceptive methods represent more than a technical advance: they are the instrument of a true social revolution-the "first reproductive revolution" in the history of humanity, an achievement of the second part of the 20th century, when modern, effective methods became available. Today a great diversity of techniques have been made available and-thanks to them, fertility rates have decreased from 5.1 in 1950 to 3.7 in 1990. As a consequence, the growth of human population that had more than tripled, from 1.8 to more than 6 billion in just one century, is today being brought under control. At the turn of the millennium, all over the world, more than 600 million married women are using contraception, with nearly 500 million in developing countries. Among married women, contraceptive use rose in all but two developing countries surveyed more than once since 1990. Among unmarried, sexually active women, it grew in 21 of 25 countries recently surveyed. Hormonal contraception, the best known method, first made available as a daily pill, can today be administered through seven different routes: intramuscularly, intranasally, intrauterus, intravaginally, orally, subcutaneously, and transdermally. In the field of oral contraception, new strategies include further dose reduction, the synthesis of new active molecules, and new administration schedules. A new minipill (progestin-only preparation) containing desogestrel has been recently marketed in a number of countries and is capable of consistently inhibiting ovulation in most women. New contraceptive rings to be inserted in the vagina offer a novel approach by providing a sustained release of steroids and low failure rates. The transdermal route for delivering contraceptive steroids is now established via a contraceptive patch, a spray, or a gel. The intramuscular route has also seen new products with the marketing of improved monthly injectable preparations containing an estrogen and a progestin. After the first device capable of delivering progesterone directly into the uterus was withdrawn, a new system releasing locally 20 microg evonorgestrel is today marketed in a majority of countries with excellent contraceptive and therapeutic performance. Finally, several subcutaneously implanted systems have been developed: contraceptive "rods," where the polymeric matrix is mixed with the steroid and "capsules" made of a hollow polymer tube filled with free steroid crystals. New advances have also been made in nonhormonal intrauterine contraception with the development of "frameless" devices. The HIV/AIDS pandemic forced policy makers to look for ways to protect young people from sexually transmitted diseases as well as from untimely pregnancies. This led to the development of the so-called dual protection method, involving the use of a physical barrier (condom) as well as that of a second, highly effective contraceptive method. More complex is the situation with antifertility vaccines, still at a preliminary stage of development and unlikely to be in widespread use for years to come. Last, but not least, work is in progress to provide effective emergency contraception after an unprotected intercourse. Very promising in this area is the use of selective progesterone receptor modulators (antiprogestins).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17308130     DOI: 10.1196/annals.1365.002

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

Review 1.  GPER modulators: Opportunity Nox on the heels of a class Akt.

Authors:  Eric R Prossnitz
Journal:  J Steroid Biochem Mol Biol       Date:  2017-03-08       Impact factor: 4.292

Review 2.  International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators.

Authors:  Eric R Prossnitz; Jeffrey B Arterburn
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 3.  Role of Estrogens in Menstrual Migraine.

Authors:  Rossella E Nappi; Lara Tiranini; Simona Sacco; Eleonora De Matteis; Roberto De Icco; Cristina Tassorelli
Journal:  Cells       Date:  2022-04-15       Impact factor: 7.666

4.  Association between duration of oral contraceptive use and risk of hypertension: A meta-analysis.

Authors:  Hui Liu; Jie Yao; Weijing Wang; Dongfeng Zhang
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-06-13       Impact factor: 3.738

5.  Association between Oral Contraceptive Use and the High-Sensitivity C-Reactive Protein Level in Premenopausal Korean Women.

Authors:  Hyejin Park
Journal:  Healthcare (Basel)       Date:  2022-02-12

6.  Birth control pills and risk of hypothyroidism: a cross-sectional study of the National Health and Nutrition Examination Survey, 2007-2012.

Authors:  Yuxuan Qiu; Yuanyuan Hu; Zhichao Xing; Qingyu Fu; Jingqiang Zhu; Anping Su
Journal:  BMJ Open       Date:  2021-06-23       Impact factor: 2.692

7.  Associations between oral contraceptive use and risks of hypertension and prehypertension in a cross-sectional study of Korean women.

Authors:  Hyejin Park; Kisok Kim
Journal:  BMC Womens Health       Date:  2013-10-21       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.